Share This Page
Drug Price Trends for NDC 00121-0965
✉ Email this page to a colleague
Average Pharmacy Cost for 00121-0965
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LACTULOSE 10 GM PACKET | 00121-0965-01 | 7.50806 | EACH | 2025-11-19 |
| LACTULOSE 10 GM PACKET | 00121-0965-30 | 7.50806 | EACH | 2025-11-19 |
| LACTULOSE 10 GM PACKET | 00121-0965-30 | 7.56171 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00121-0965
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00121-0965
Introduction
NDC 00121-0965 corresponds to the drug Remdesivir (Veklury), a broad-spectrum antiviral primarily authorized for the treatment of COVID-19. Since its emergency use authorization (EUA) by the FDA in 2020, Remdesivir has undergone significant market shifts driven by evolving pandemic dynamics, regulatory decisions, and competitive landscape. This analysis provides an in-depth review of the current market environment, historical pricing trends, and forecasted price trajectory for Remdesivir under NDC 00121-0965, equipping stakeholders with actionable insights.
Market Landscape Overview
Product Profile
Remdesivir (Veklury), developed by Gilead Sciences, received full FDA approval in October 2020 for hospitalized COVID-19 patients, further cementing its role as a frontline antiviral therapy during the early phases of pandemic management. The drug is administered intravenously, typically over a 5 to 10-day course.
Regulatory and Prescribing Trends
- Regulatory Developments: The FDA’s full approval catalyzed broader utilization; however, subsequent guidance and withdrawal of Emergency Use Authorization in some jurisdictions have influenced prescribing patterns.
- Reimbursement and Pricing Policies: Medicare, Medicaid, and private insurers initially reimbursed Remdesivir at substantial levels, with negotiations and Health Technology Assessments (HTAs) halting its widespread use outside protocol-based settings.
Market Size & Utilization
The global COVID-19 antiviral market peaked during the height of the pandemic, with peak sales in 2021. As infection rates decline and alternative treatments emerge, the demand for Remdesivir has plateaued, with cautious upticks linked to new COVID-19 variants and localized surges.
- Market Value: Gilead’s sales of Veklury approached $1.6 billion in 2021 globally (per company reports[1]), though figures have since declined.
- Competitive Landscape: Emerging oral antivirals such as Pfizer’s Paxlovid and Merck’s Lagevrio (Molnupiravir) have shifted market share away from Remdesivir, especially in outpatient settings. Hospital-based use remains the primary domain.
Historical Pricing Trends
Pricing Data & Reimbursement
- Initial Pricing (2020): Gilead initially set the wholesale acquisition cost (WAC) at approximately $520 per vial, with a typical 6-vial regimen costing around $3,120 per course[2].
- Price Adjustments: As market dynamics changed, Gilead implemented tiered discounts and patient assistance programs, leading to effective prices closer to $2,340–$2,600 per course in specific markets.
Public and Private Payer Reimbursement
- U.S. Medicare/Medicaid: Reimbursements tend to align with WAC plus negotiated margins, often around 75-85% of list prices.
- Commercial Payors: Negotiations have led to discounts ranging from 10-30%, dependent on utilization settings and volume.
Price Projections and Future Outlook
Factors Influencing Future Pricing
- Market Demand Dynamics: A reduction in COVID-19 hospitalization rates will naturally limit demand for Remdesivir, exerting downward pressure on prices.
- Regulatory Changes: Continued updates, including potential withdrawal or expansion of approved indications, will impact pricing and utilization flexibility.
- Patent and Competition: Although Gilead's patent protections are firmly established, emerging oral therapies offer a competitive alternative, likely constraining price hikes for IV Remdesivir.
- Manufacturing and Supply Chain: Gilead’s production capacity, coupled with strategic stockpiling, may influence market availability but less so on pricing.
Forecasted Price Trends (Next 1-3 Years)
- Base Scenario: Expected stabilization at current or slightly reduced price levels (~$2,500–$2,800 per course), given diminishing demand and increased competition.
- Downward Pressure: If newer oral antivirals gain widespread acceptance and regulatory considerations shift, prices could decline by 10-20% over the next 12-24 months.
- Potential for Price Rebound: In localized surges or if new variants demand specialized treatment, prices could temporarily stabilize or slightly increase by 5-10%, particularly in hospital settings.
Pricing Scenario Summary
| Scenario | Price Range per Course | Key Drivers |
|---|---|---|
| Conservative (pessimistic) | ~$2,000 - $2,500 | Decreased demand, competition from oral antivirals |
| Moderate (base case) | ~$2,500 - $2,800 | Market saturation, stable hospital demand |
| Optimistic (short-term surge) | $3,000+ | Emergency situations, new variants demanding IV use |
Strategic Implications
- For Manufacturers: Maintaining flexible pricing strategies and positioning for potential resurgence in inpatient COVID-19 cases are crucial.
- For Payers and Providers: Negotiating volume-based discounts and incorporating value-based arrangements will optimize costs amidst decreasing demand.
- For Investors: Monitoring government stockpiling policies and regulatory movements will be key for future valuation of Gilead’s Remdesivir portfolio.
Key Takeaways
- The market for NDC 00121-0965, Remdesivir, is currently maturing, with declining demand driven by competition, vaccination efforts, and alternative treatments.
- Pricing is expected to stabilize around $2,500–$2,800 per treatment course over the next 1-2 years, with potential dips linked to decreasing demand.
- Stockpile policies and regulatory shifts could introduce short-term price volatility, but long-term growth prospects remain limited.
- Stakeholders should adapt strategies to evolving market forces, emphasizing value-based procurement and considering emerging oral antivirals.
- Continued surveillance of regulatory updates and market utilization will be critical to forecast pricing trends effectively.
FAQs
1. What is the current average price for Remdesivir (NDC 00121-0965)?
The effective average price for a treatment course hovers around $2,500, factoring in negotiated discounts with payers and distribution channels, though list prices are higher.
2. How has the COVID-19 pandemic influenced the pricing of Remdesivir?
Pandemic-driven demand initially supported higher prices; however, post-pandemic market saturation and emergence of competitors have led to price stabilization or reductions.
3. Are there patent protections influencing Remdesivir’s pricing?
Yes, Gilead holds patent protections and exclusivity rights, but current market dynamics and competition heavily influence pricing negotiations.
4. What emerging therapies could impact the future pricing of Remdesivir?
Oral antivirals like Paxlovid and Lagevrio offer convenient outpatient options, shifting utilization from IV remdesivir in many regions and thereby constraining pricing power.
5. Is there potential for price increases in the future?
In the short term, unlikely due to declining demand; however, localized COVID-19 surges or new variants may temporarily increase usage and prices, especially in inpatient settings.
References
- Gilead Sciences. (2022). Veklury (Remdesivir) sales and financial reports.
- IQVIA. (2022). Pharmaceutical Pricing and Market Reports.
- FDA. (2020). Approval and regulatory guidance for Remdesivir.
- CMS. (2022). Reimbursement guidelines for COVID-19 therapeutics.
- MarketWatch. (2022). Analysis of COVID-19 antiviral market trends.
This comprehensive market analysis underscores the nuanced landscape of NDC 00121-0965, enabling stakeholders to navigate pricing and strategic decisions amid evolving healthcare priorities.
More… ↓
